Primary atopic disorders: Monogenic insights into immunity

Area of Science:

• Immunology
• Genetics
• Allergy Research

Background:

• Primary atopic disorders (PADs) are monogenic diseases presenting as severe, early-onset allergic inflammation, often with immune deficiency.
• PADs are increasingly recognized as valuable human models for dissecting immune homeostasis and allergic disease pathogenesis.
• Next-generation sequencing has accelerated the discovery of genes implicated in PADs, highlighting complex regulatory system disruptions.

Purpose of the Study:

• To synthesize insights from genetically defined PADs to elucidate mechanisms of impaired tolerance and type 2 inflammation.
• To illustrate how defects in various biological systems converge to cause allergic inflammation.
• To provide a framework for precision therapy development in PADs and inform common atopy.

Main Methods:

• Review and synthesis of findings from genetically defined primary atopic disorders.
• Analysis of defects in epithelial barrier function, immune signaling, cytoskeletal organization, and lymphocyte regulation.
• Integration of genetic discoveries with immunological pathways leading to allergic inflammation.

Main Results:

• Defects in epithelial barriers, immune signaling, cytoskeletal organization, antigen receptor pathways, lymphocyte repertoire, and regulatory networks contribute to impaired tolerance.
• These diverse genetic defects converge on persistent type 2 inflammation, characteristic of PADs.
• Understanding these pathways offers mechanistic insights into both rare and common forms of atopy.

Conclusions:

• Genetically defined PADs offer critical insights into the complex pathophysiology of allergic inflammation.
• PADs provide a foundation for developing precision therapies, including cytokine inhibitors, JAK inhibitors, biologics, and gene therapies.
• Insights from PADs bridge the understanding of rare and common allergic diseases, improving therapeutic strategies.